2023
Transcultural Lifestyle Medicine in Type 2 Diabetes Care: Narrative Review of the Literature
GONZALEZ-RIVAS, Juan P., Iuliia PAVLOVSKA, Anna POLCROVÁ, Ramfis NIETO-MARTINEZ, Jeffrey I. MECHANICK et. al.Základní údaje
Originální název
Transcultural Lifestyle Medicine in Type 2 Diabetes Care: Narrative Review of the Literature
Autoři
GONZALEZ-RIVAS, Juan P. (garant), Iuliia PAVLOVSKA (804 Ukrajina, domácí), Anna POLCROVÁ (203 Česká republika, domácí), Ramfis NIETO-MARTINEZ a Jeffrey I. MECHANICK
Vydání
AMERICAN JOURNAL OF LIFESTYLE MEDICINE, THOUSAND OAKS, SAGE PUBLICATIONS INC, 2023, 1559-8276
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30304 Public and environmental health
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 1.900 v roce 2022
Kód RIV
RIV/00216224:14110/23:00130012
Organizační jednotka
Lékařská fakulta
UT WoS
000806385700001
Klíčová slova anglicky
dysglycemia; culture; lifestyle medicine; prevention; transcultural; type 2 diabetes
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 1. 2024 10:10, Mgr. Tereza Miškechová
Anotace
V originále
Disparities in type 2 diabetes (T2D) care is a global problem across diverse cultures. The Dysglycemia-Based Chronic Disease (DBCD) model promotes early and sustainable interventions along the insulin resistance (stage 1), prediabetes (stage 2), T2D (stage 3), and complications (stage 4) spectrum. In this model, lifestyle medicine is the cornerstone of preventive care to reduce DBCD progression and the socioeconomic/biological burden of disease. A comprehensive literature review, spanning 2000 to 2021, was performed and 55 studies were included examining the effects of lifestyle medicine and their cultural adaptions with different prevention modalities. In stage 1, primordial prevention targets modifiable primary drivers (behavior and environment), unhealthy lifestyles, abnormal adiposity, and insulin resistance with educational and motivational health promotion activities at individual, group, community, and population-based scales. Primary, secondary, and tertiary prevention targets individuals with mild hyperglycemia, severe hyperglycemia, and complications, respectively, using programs that incorporate structured lifestyle interventions. Culturally adapted lifestyle change in primary and secondary prevention improved quality of life and biomarkers, but with a limited impact of tertiary prevention on cardiovascular events. In conclusion, lifestyle medicine with cultural adaptations is an integral part of preventive care in patients with T2D. However, considerable research gaps exist, especially for tertiary prevention.